Solid Biosciences Inc. (SLDB)

Solid Biosciences’ loss narrowed versus a year ago in the second fiscal quarter of 2026, with preliminary results reported August 6, 2026 showing GAAP net income of about -$54.8 million, a -38.8% year-over-year move from about -$39.5 million a year ago. On the earnings line, EPS of -$0.38 topped the -$0.46 estimate by $0.08. Profitability remained negative, with operating income of roughly -$57.4 million as the clinical-stage Duchenne muscular dystrophy gene therapy pipeline, including programs such as SGT-001 and SGT-003, continued to drive spending rather than product revenue. Cash usage also stayed elevated, with negative operating cash flow of around -$52.6 million in the quarter. For the next period, consensus calls for EPS of -$0.37.